The effect of the original, domestically manufactured, derivatives of 3-hydroxypyridine and succinic acid (emoxipine, reamberin and mexidol) on the dynamics of monoamine oxidase (MAO-A and MAO-B) activity was studied as compared with the hippocampal level of biogenic amines (serotonin and dopamine) during the first two weeks of alloxan-induced diabetes in rats. It was shown that during this period the hippocampus develops a buildup of dopamine and serotonin against the background of unchanged MAO-A and MAO-B activities. It was established that a 14-day administration of emoxipine, reamberin and mexidol in animals with alloxan-induced DM at doses equivalent to the human therapeutic range prevented an increase in paleocortical serotonin and dopamine levels. Succinate-containing drugs (reamberin and mexidol) induced a parallel decrease in the MAO-B activity in the Ammon’s horn of diabetic animals. Mexidol, which is a co-derivative of 3-hydroxypyridine and succinic acid, induced additionally decreased the hippocampal MAO-A activity. In terms of the severity of the above effects, reamberin and mexidol were not inferior to α-lipoic acid which was used as a reference drug. An isolated derivative of 3-hydroxypyridine (emoxipine), in contrast to reamberin, mexidol and α-lipoic acid, promoted normalization of paleocortical serotonin and dopamine levels but did not affect hippocampal MAO-A and MAO-B activities in rats with alloxan-induced DM. 3-hydroxypyridine derivatives (emoxipine and mexidol), in contrast to reamberin and α-lipoic acid, induced no transient increase in MAO activity and monoamine levels in the hippocampus of diabetic rats. These results are consistent with the previously demonstrated superiority of emoxipine and mexidol over reamberin and α-lipoic acid in the intensity of their cerebroprotective effects in alloxan-induced DM.

中文翻译：

---

3-羟基吡啶和琥珀酸衍生物对四氧嘧啶致糖尿病大鼠海马单胺氧化酶活性的影响

研究了原始的、国产的、3-羟基吡啶和琥珀酸衍生物（emoxipine、reamberin 和 mexidol）对单胺氧化酶（MAO-A 和 MAO-B）动态的影响，并与生物源的海马水平进行了比较。在大鼠四氧嘧啶诱导的糖尿病的前两周内，胺（血清素和多巴胺）。结果表明，在此期间，在 MAO-A 和 MAO-B 活性不变的背景下，海马体会产生多巴胺和血清素的积累。已经确定，在四氧嘧啶诱导的 DM 动物中以相当于人类治疗范围的剂量服用 14 天的 emoxipine、reamberin 和 mexidol 可防止古皮质血清素和多巴胺水平的增加。含琥珀酸盐的药物（reamberin 和 mexidol）诱导糖尿病动物阿蒙角中 MAO-B 活性的平行降低。Mexidol 是 3-羟基吡啶和琥珀酸的共衍生物，另外诱导海马 MAO-A 活性降低。就上述影响的严重程度而言，reamberin 和 mexidol 并不逊色于用作参考药物的α-硫辛酸。与 reamberin、mexidol 和 α-硫辛酸相比，一种分离的 3-羟基吡啶衍生物（emoxipine）促进了古皮质血清素和多巴胺水平的正常化，但不影响四氧嘧啶诱导的大鼠海马 MAO-A 和 MAO-B 的活性DM。3-羟基吡啶衍生物（emoxipine 和 mexidol），与 reamberin 和 α-硫辛酸相反，诱导糖尿病大鼠海马中的 MAO 活性和单胺水平没有瞬时增加。这些结果与先前证明的 emoxipine 和 mexidol 在四氧嘧啶诱导的 DM 中的脑保护作用强度优于 reamberin 和 α-硫辛酸。